Takotsubo Cardiomyopathy

Subarachnoid Hemorrhage

Patient's age, sex, comorbidities, medications, the exact time point of bleeding, the circumstances of bleeding neurological and cardiological status are recorded, laboratory tests, Transcranial Color Doppler (TCCD), echocardiography and chest X-ray examinations are carried out within 24 hours after the patient is being admitted to the ICU.

bleeding, intraventricular and/ or intracerebral hemorrhage.

Echocardiographic Correlates of Acute Heart Failure, Cardiogenic Shock, and In-Hospital Mortality in Tako-Tsubo Cardiomyopathy

Stress Cardiomyopathy: Case Series and the Review of Literature Vinoda Sharma, MRCP, Manivannan Srinivasan, MRCP, Daniel Mark Sheehan, MBCH, Adrian Ionescu, MRCP

Natural History and Expansive Clinical Profile of Stress (Tako-Tsubo) Cardiomyopathy Scott W. Sharkey, MD

Takotsubo cardiomyopathy — The current state of knowledge Agata Bielecka-Dabrowa, Dimitri P. Mikhailidis, Simon Hannam, Jacek Rysz, Marta Michalska, Yoshihiro J. Akashi, Maciej Banach

Systematic review and meta-analysis of incidence and correlates of recurrence of takotsubo cardiomyopathy☆ Kuljit Singhcorrespondenceemail, Kristin Carson, Zafar Usmani, Gagandeep Sawhney, Ranjit Shah, John Horowitz

Echocardiographic Correlates of Acute Heart Failure, Cardiogenic Shock, and In-Hospital Mortality in Tako-Tsubo Cardiomyopathy Rodolfo Citro, MD

Usefulness of MRI in takotsubo cardiomyopathy: a review of the literature Andres Alejandro Kohan1

UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care

Takotsubo Cardiomyopathy in Patients Suffering From Acute Non-traumatic Subarachnoid Hemorrhage

Incidence, Influencing Factors and Outcome of Takotsubo Cardiomyopathy in Patients Suffering From Acute Non-traumatic Subarachnoid Hemorrhage

The amount of urine collected in 24 hours and determination of urine metanephrine, normetanephrine levels

The level of metanephrine and normetanephrine from 24-hour collected urine should be measured again after 1 and 6 months in case of patients where TS was diagnosed.

Cardiac troponin I (cTnI), creatine kinase (CK), CK-MB, Brain natriuretic peptide (BNP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP)

Echocardiography documented with video recording

Clinical outcome (GOS), quality of life (Bartel Index) and Karnofsky scores

Tamas Vegh, MD

assistant lecturer anesthesiologist and intensive care specialist

University of Debrecen

Patients presenting with stress induced cardiomyopathy, after meeting the Mayo criteria (normal coronary anatomy, EKG changes/Enzyme abnormalities, wall motion abnormalities consistent with stress induced cardiomyopathy and no evidence of pheochromocytoma) and signing informed consent, will receive an I123-mIBG scan to determine the sympathetic function of the heart during the acute presentation and after functional recovery.

Patients with stress induced cardiomyopathy, by the Mayo criteria (normal coronary anatomy, EKG changes/Enzyme abnormalities, wall motion abnormalities consistent with stress induced cardiomyopathy and no evidence of pheochromocytoma) and signing informed consent, will receive an I123-mIBG scan to determine the sympathetic function of the heart during the acute presentation and after functional recovery.
I-123 radiolabeled metaiodobenzylguanidine cardiac imaging: All subjects will receive an intravenous injection of 10 mCi (370 MBq) of 123I-mIBG. A ±10% tolerance of the nominal dose will be allowed, thus yielding an acceptable dose range of 9 to 11 mCi (333 to 407 MBq). The patient will have planar and SPECT imaging performed after the dose is administered. This dosing and imaging procedure will be performed during the acute phase and after the patient has recovered cardiac function, approximately 6 weeks later.

Stress Induced Cardiomyopathy Patients

Sex: Female, Male

Region of Enrollment

Number of participants who had an abnormal regional uptake of I-123 mIBG at baseline (acute phase) and the number of participants who had an abnormal I-123 mIBG uptake on follow up (recovery phase)

Number of Participants Who Had an Abnormal Regional Uptake of I-123 mIBG at Baseline (Acute Phase) and the Number of Participants Who Had an Abnormal I-123 mIBG Uptake on Follow up (Recovery Phase)

Overall Study

Dr. Prem Soman

Stress Induced Cardiomyopathy

All subjects will receive an intravenous injection of 10 mCi (370 MBq) of 123I-mIBG. A ±10% tolerance of the nominal dose will be allowed, thus yielding an acceptable dose range of 9 to 11 mCi (333 to 407 MBq). The investigational medicinal product will be administered in a volume of 5 mL (diluted using 0.9% sodium chloride as needed) and injected over 1 to 2 minutes. The patient will have planar and SPECT imaging performed after the dose is administered. This dosing and imaging procedure will be performed during the acute phase and after the patient has recovered cardiac function, approximately 6 weeks later. This means that each study subject will receive a total of 2 doses of I123-mIBG at 2 different time points.

takotsubo cardiomyopathy/edema

Takotsubo Cardiomyopathy in Patients Suffering From Acute Non-traumatic Subarachnoid Hemorrhage

Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG

Il database di erbe medicinali più completo supportato dalla scienza